CA2332625A1 - Interaction de precurseur de la proteine beta-amyloide humaine (.beta.-app) et de proteine humaine du type lon-protease (hslon) - Google Patents

Interaction de precurseur de la proteine beta-amyloide humaine (.beta.-app) et de proteine humaine du type lon-protease (hslon) Download PDF

Info

Publication number: CA2332625A1
Authority: CA; Canada
Prior art keywords: app; hslon; complex; beta; derivative
Prior art date: 1998-07-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002332625A

Other languages

English (en)

Inventor

Krishnan Nandabalan

Meijia Yang

Vincent Peter Schulz

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

CuraGen Corp

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-10

Filing date

1999-07-08

Publication date

2000-01-20

1999-07-08 Application filed by Individual filed Critical Individual

2000-01-20 Publication of CA2332625A1 publication Critical patent/CA2332625A1/fr

Status Abandoned legal-status Critical Current

Links

230000003993 interaction Effects 0.000 title abstract description 28
101001033280 Homo sapiens Cytokine receptor common subunit beta Proteins 0.000 title description 3
102000055647 human CSF2RB Human genes 0.000 title description 3
101710137189 Amyloid-beta A4 protein Proteins 0.000 title description 2
102100022704 Amyloid-beta precursor protein Human genes 0.000 title description 2
101710151993 Amyloid-beta precursor protein Proteins 0.000 title description 2
101001064870 Homo sapiens Lon protease homolog, mitochondrial Proteins 0.000 title description 2
DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 title description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 166
238000000034 method Methods 0.000 claims abstract description 149
239000012634 fragment Substances 0.000 claims abstract description 115
208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 42
230000015572 biosynthetic process Effects 0.000 claims abstract description 35
206010012601 diabetes mellitus Diseases 0.000 claims abstract description 35
230000004770 neurodegeneration Effects 0.000 claims abstract description 35
206010011878 Deafness Diseases 0.000 claims abstract description 34
208000016354 hearing loss disease Diseases 0.000 claims abstract description 34
208000007466 Male Infertility Diseases 0.000 claims abstract description 32
238000012216 screening Methods 0.000 claims abstract description 29
231100000888 hearing loss Toxicity 0.000 claims abstract description 26
230000010370 hearing loss Effects 0.000 claims abstract description 26
208000031229 Cardiomyopathies Diseases 0.000 claims abstract description 23
206010052641 Mitochondrial DNA mutation Diseases 0.000 claims abstract 5
108090000623 proteins and genes Proteins 0.000 claims description 210
150000007523 nucleic acids Chemical class 0.000 claims description 143
102000004169 proteins and genes Human genes 0.000 claims description 142
102000039446 nucleic acids Human genes 0.000 claims description 126
108020004707 nucleic acids Proteins 0.000 claims description 126
230000000694 effects Effects 0.000 claims description 121
210000004027 cell Anatomy 0.000 claims description 111
208000035475 disorder Diseases 0.000 claims description 87
201000010099 disease Diseases 0.000 claims description 75
230000027455 binding Effects 0.000 claims description 51
238000011282 treatment Methods 0.000 claims description 35
239000002773 nucleotide Substances 0.000 claims description 32
125000003729 nucleotide group Chemical group 0.000 claims description 32
230000006870 function Effects 0.000 claims description 30
108020001507 fusion proteins Proteins 0.000 claims description 29
102000037865 fusion proteins Human genes 0.000 claims description 29
238000000338 in vitro Methods 0.000 claims description 27
239000013598 vector Substances 0.000 claims description 26
241001465754 Metazoa Species 0.000 claims description 24
150000001413 amino acids Chemical class 0.000 claims description 24
230000000692 anti-sense effect Effects 0.000 claims description 24
239000000523 sample Substances 0.000 claims description 23
108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
230000001594 aberrant effect Effects 0.000 claims description 17
239000008194 pharmaceutical composition Substances 0.000 claims description 17
230000002265 prevention Effects 0.000 claims description 17
230000004071 biological effect Effects 0.000 claims description 16
210000004748 cultured cell Anatomy 0.000 claims description 13
230000005714 functional activity Effects 0.000 claims description 13
108091026890 Coding region Proteins 0.000 claims description 12
239000003937 drug carrier Substances 0.000 claims description 12
230000008859 change Effects 0.000 claims description 10
238000002744 homologous recombination Methods 0.000 claims description 8
230000006801 homologous recombination Effects 0.000 claims description 8
230000003247 decreasing effect Effects 0.000 claims description 7
239000000126 substance Substances 0.000 claims description 5
230000003321 amplification Effects 0.000 claims description 4
238000003199 nucleic acid amplification method Methods 0.000 claims description 4
108090000144 Human Proteins Proteins 0.000 claims description 3
102000003839 Human Proteins Human genes 0.000 claims description 3
108020004711 Nucleic Acid Probes Proteins 0.000 claims 1
108700019146 Transgenes Proteins 0.000 claims 1
238000002743 insertional mutagenesis Methods 0.000 claims 1
238000012544 monitoring process Methods 0.000 claims 1
239000002853 nucleic acid probe Substances 0.000 claims 1
230000037452 priming Effects 0.000 claims 1
108700026220 vif Genes Proteins 0.000 claims 1
208000037765 diseases and disorders Diseases 0.000 abstract description 14
238000003158 yeast two-hybrid assay Methods 0.000 abstract description 5
230000001976 improved effect Effects 0.000 abstract description 4
235000018102 proteins Nutrition 0.000 description 126
230000001225 therapeutic effect Effects 0.000 description 89
210000003470 mitochondria Anatomy 0.000 description 49
230000014509 gene expression Effects 0.000 description 44
238000003556 assay Methods 0.000 description 42
239000003814 drug Substances 0.000 description 30
230000009946 DNA mutation Effects 0.000 description 28
240000004808 Saccharomyces cerevisiae Species 0.000 description 28
235000001014 amino acid Nutrition 0.000 description 24
108020004414 DNA Proteins 0.000 description 23
229940024606 amino acid Drugs 0.000 description 23
238000010171 animal model Methods 0.000 description 22
208000024827 Alzheimer disease Diseases 0.000 description 21
238000012360 testing method Methods 0.000 description 21
230000009918 complex formation Effects 0.000 description 20
230000000295 complement effect Effects 0.000 description 19
208000024891 symptom Diseases 0.000 description 19
230000013011 mating Effects 0.000 description 18
230000004568 DNA-binding Effects 0.000 description 17
239000013604 expression vector Substances 0.000 description 16
238000009396 hybridization Methods 0.000 description 15
108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
238000001415 gene therapy Methods 0.000 description 14
238000003018 immunoassay Methods 0.000 description 14
108090000765 processed proteins & peptides Proteins 0.000 description 14
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 13
238000000099 in vitro assay Methods 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
108020004999 messenger RNA Proteins 0.000 description 12
125000003275 alpha amino acid group Chemical group 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
238000005462 in vivo assay Methods 0.000 description 11
230000035772 mutation Effects 0.000 description 11
239000000243 solution Substances 0.000 description 11
210000001519 tissue Anatomy 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 10
239000002299 complementary DNA Substances 0.000 description 10
238000001514 detection method Methods 0.000 description 10
239000003112 inhibitor Substances 0.000 description 10
239000000203 mixture Substances 0.000 description 10
230000001105 regulatory effect Effects 0.000 description 10
238000013518 transcription Methods 0.000 description 10
230000035897 transcription Effects 0.000 description 10
210000005253 yeast cell Anatomy 0.000 description 10
241000700159 Rattus Species 0.000 description 9
230000004913 activation Effects 0.000 description 9
230000009467 reduction Effects 0.000 description 9
210000000130 stem cell Anatomy 0.000 description 9
238000012546 transfer Methods 0.000 description 9
108700008625 Reporter Genes Proteins 0.000 description 8
231100000895 deafness Toxicity 0.000 description 8
230000004927 fusion Effects 0.000 description 8
238000002347 injection Methods 0.000 description 8
239000007924 injection Substances 0.000 description 8
230000004048 modification Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
241000894007 species Species 0.000 description 8
208000011580 syndromic disease Diseases 0.000 description 8
206010012289 Dementia Diseases 0.000 description 7
201000010374 Down Syndrome Diseases 0.000 description 7
108010001515 Galectin 4 Proteins 0.000 description 7
102100039556 Galectin-4 Human genes 0.000 description 7
206010044688 Trisomy 21 Diseases 0.000 description 7
238000004458 analytical method Methods 0.000 description 7
210000004556 brain Anatomy 0.000 description 7
230000012010 growth Effects 0.000 description 7
238000003752 polymerase chain reaction Methods 0.000 description 7
230000006916 protein interaction Effects 0.000 description 7
230000014616 translation Effects 0.000 description 7
206010011891 Deafness neurosensory Diseases 0.000 description 6
238000002965 ELISA Methods 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
108091034117 Oligonucleotide Proteins 0.000 description 6
108700026244 Open Reading Frames Proteins 0.000 description 6
208000009966 Sensorineural Hearing Loss Diseases 0.000 description 6
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 6
238000013459 approach Methods 0.000 description 6
230000002950 deficient Effects 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
230000004064 dysfunction Effects 0.000 description 6
230000035790 physiological processes and functions Effects 0.000 description 6
231100000879 sensorineural hearing loss Toxicity 0.000 description 6
208000023573 sensorineural hearing loss disease Diseases 0.000 description 6
108091006106 transcriptional activators Proteins 0.000 description 6
238000011830 transgenic mouse model Methods 0.000 description 6
238000013519 translation Methods 0.000 description 6
241000701161 unidentified adenovirus Species 0.000 description 6
241000972773 Aulopiformes Species 0.000 description 5
241000699660 Mus musculus Species 0.000 description 5
208000018737 Parkinson disease Diseases 0.000 description 5
239000004365 Protease Substances 0.000 description 5
108020004511 Recombinant DNA Proteins 0.000 description 5
230000006907 apoptotic process Effects 0.000 description 5
150000001875 compounds Chemical class 0.000 description 5
238000003745 diagnosis Methods 0.000 description 5
210000003958 hematopoietic stem cell Anatomy 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 5
210000004185 liver Anatomy 0.000 description 5
239000003550 marker Substances 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
239000011859 microparticle Substances 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
239000013615 primer Substances 0.000 description 5
102000004196 processed proteins & peptides Human genes 0.000 description 5
235000004252 protein component Nutrition 0.000 description 5
230000002441 reversible effect Effects 0.000 description 5
108091092562 ribozyme Proteins 0.000 description 5
235000019515 salmon Nutrition 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
108090000994 Catalytic RNA Proteins 0.000 description 4
102000053642 Catalytic RNA Human genes 0.000 description 4
229920001917 Ficoll Polymers 0.000 description 4
241000282412 Homo Species 0.000 description 4
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
241000699666 Mus <mouse, genus> Species 0.000 description 4
238000012408 PCR amplification Methods 0.000 description 4
238000002105 Southern blotting Methods 0.000 description 4
230000002159 abnormal effect Effects 0.000 description 4
230000032683 aging Effects 0.000 description 4
239000000556 agonist Substances 0.000 description 4
230000004075 alteration Effects 0.000 description 4
125000000539 amino acid group Chemical group 0.000 description 4
239000005557 antagonist Substances 0.000 description 4
239000000074 antisense oligonucleotide Substances 0.000 description 4
238000012230 antisense oligonucleotides Methods 0.000 description 4
230000008436 biogenesis Effects 0.000 description 4
210000003995 blood forming stem cell Anatomy 0.000 description 4
230000004094 calcium homeostasis Effects 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
210000002889 endothelial cell Anatomy 0.000 description 4
238000009472 formulation Methods 0.000 description 4
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
238000002955 isolation Methods 0.000 description 4
239000003446 ligand Substances 0.000 description 4
239000002502 liposome Substances 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
238000007899 nucleic acid hybridization Methods 0.000 description 4
210000004940 nucleus Anatomy 0.000 description 4
230000008506 pathogenesis Effects 0.000 description 4
238000012545 processing Methods 0.000 description 4
238000004393 prognosis Methods 0.000 description 4
230000000069 prophylactic effect Effects 0.000 description 4
238000003259 recombinant expression Methods 0.000 description 4
230000000241 respiratory effect Effects 0.000 description 4
230000001177 retroviral effect Effects 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
230000002103 transcriptional effect Effects 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
238000001262 western blot Methods 0.000 description 4
108020000948 Antisense Oligonucleotides Proteins 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
241000196324 Embryophyta Species 0.000 description 3
241000238631 Hexapoda Species 0.000 description 3
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
208000021642 Muscular disease Diseases 0.000 description 3
201000009623 Myopathy Diseases 0.000 description 3
208000037273 Pathologic Processes Diseases 0.000 description 3
108091005804 Peptidases Proteins 0.000 description 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
241000714474 Rous sarcoma virus Species 0.000 description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
101150050575 URA3 gene Proteins 0.000 description 3
241000700605 Viruses Species 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
239000012190 activator Substances 0.000 description 3
238000007792 addition Methods 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000007818 agglutination assay Methods 0.000 description 3
230000037396 body weight Effects 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
230000003915 cell function Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
230000037149 energy metabolism Effects 0.000 description 3
230000001605 fetal effect Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
238000001114 immunoprecipitation Methods 0.000 description 3
230000005764 inhibitory process Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
238000007914 intraventricular administration Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000012423 maintenance Methods 0.000 description 3
239000002609 medium Substances 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
239000003094 microcapsule Substances 0.000 description 3
230000001590 oxidative effect Effects 0.000 description 3
230000009054 pathological process Effects 0.000 description 3
235000019419 proteases Nutrition 0.000 description 3
238000003127 radioimmunoassay Methods 0.000 description 3
230000010076 replication Effects 0.000 description 3
108091008146 restriction endonucleases Proteins 0.000 description 3
238000012163 sequencing technique Methods 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
230000008685 targeting Effects 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
229940035893 uracil Drugs 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
238000001086 yeast two-hybrid system Methods 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
108091006112 ATPases Proteins 0.000 description 2
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
102000057290 Adenosine Triphosphatases Human genes 0.000 description 2
208000037259 Amyloid Plaque Diseases 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
206010064539 Autoimmune myocarditis Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
102000000844 Cell Surface Receptors Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
101150009006 HIS3 gene Proteins 0.000 description 2
101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
108090000157 Metallothionein Proteins 0.000 description 2
108020005196 Mitochondrial DNA Proteins 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
108090000526 Papain Proteins 0.000 description 2
108091008103 RNA aptamers Proteins 0.000 description 2
101100394989 Rhodopseudomonas palustris (strain ATCC BAA-98 / CGA009) hisI gene Proteins 0.000 description 2
102000006601 Thymidine Kinase Human genes 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
239000013543 active substance Substances 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000002238 attenuated effect Effects 0.000 description 2
238000000376 autoradiography Methods 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000013602 bacteriophage vector Substances 0.000 description 2
230000002146 bilateral effect Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
210000004413 cardiac myocyte Anatomy 0.000 description 2
230000011748 cell maturation Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
239000013599 cloning vector Substances 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000012875 competitive assay Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
230000003412 degenerative effect Effects 0.000 description 2
-1 derivatives Substances 0.000 description 2
238000013461 design Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
210000002919 epithelial cell Anatomy 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
238000012817 gel-diffusion technique Methods 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
208000019622 heart disease Diseases 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000003365 immunocytochemistry Methods 0.000 description 2
230000000951 immunodiffusion Effects 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
239000000411 inducer Substances 0.000 description 2
230000001939 inductive effect Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
230000031146 intracellular signal transduction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
238000007834 ligase chain reaction Methods 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
210000001178 neural stem cell Anatomy 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
230000036963 noncompetitive effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
206010030875 ophthalmoplegia Diseases 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
230000036542 oxidative stress Effects 0.000 description 2
229940055729 papain Drugs 0.000 description 2
235000019834 papain Nutrition 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 2
239000002243 precursor Substances 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
108020001580 protein domains Proteins 0.000 description 2
238000002005 protein protein interaction detection Methods 0.000 description 2
238000002762 protein-protein interaction assay Methods 0.000 description 2
230000004850 protein–protein interaction Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000010837 receptor-mediated endocytosis Effects 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000006798 recombination Effects 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000022983 regulation of cell cycle Effects 0.000 description 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
210000000717 sertoli cell Anatomy 0.000 description 2
238000012916 structural analysis Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
230000009885 systemic effect Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
230000005945 translocation Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
230000009385 viral infection Effects 0.000 description 2
MNULEGDCPYONBU-WMBHJXFZSA-N (1r,4s,5e,5'r,6'r,7e,10s,11r,12s,14r,15s,16s,18r,19s,20r,21e,25s,26r,27s,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trio Polymers O([C@@H]1CC[C@@H](/C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)O[C@H]([C@H]2C)[C@H]1C)CC)[C@]12CC[C@@H](C)[C@@H](C[C@H](C)O)O1 MNULEGDCPYONBU-WMBHJXFZSA-N 0.000 description 1
MNULEGDCPYONBU-DJRUDOHVSA-N (1s,4r,5z,5'r,6'r,7e,10s,11r,12s,14r,15s,18r,19r,20s,21e,26r,27s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers O([C@H]1CC[C@H](\C=C/C=C/C[C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@H](C)[C@@H](O)C(C)C(=O)[C@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)OC([C@H]2C)C1C)CC)[C@]12CC[C@@H](C)[C@@H](CC(C)O)O1 MNULEGDCPYONBU-DJRUDOHVSA-N 0.000 description 1
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
MNULEGDCPYONBU-YNZHUHFTSA-N (4Z,18Z,20Z)-22-ethyl-7,11,14,15-tetrahydroxy-6'-(2-hydroxypropyl)-5',6,8,10,12,14,16,28,29-nonamethylspiro[2,26-dioxabicyclo[23.3.1]nonacosa-4,18,20-triene-27,2'-oxane]-3,9,13-trione Polymers CC1C(C2C)OC(=O)\C=C/C(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)C\C=C/C=C\C(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-YNZHUHFTSA-N 0.000 description 1
MNULEGDCPYONBU-VVXVDZGXSA-N (5e,5'r,7e,10s,11r,12s,14s,15r,16r,18r,19s,20r,21e,26r,29s)-4-ethyl-11,12,15,19-tetrahydroxy-6'-[(2s)-2-hydroxypropyl]-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers C([C@H](C)[C@@H](O)[C@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)/C=C/C(=O)OC([C@H]1C)[C@H]2C)\C=C\C=C\C(CC)CCC2OC21CC[C@@H](C)C(C[C@H](C)O)O2 MNULEGDCPYONBU-VVXVDZGXSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
MNULEGDCPYONBU-UHFFFAOYSA-N 4-ethyl-11,12,15,19-tetrahydroxy-6'-(2-hydroxypropyl)-5',10,12,14,16,18,20,26,29-nonamethylspiro[24,28-dioxabicyclo[23.3.1]nonacosa-5,7,21-triene-27,2'-oxane]-13,17,23-trione Polymers CC1C(C2C)OC(=O)C=CC(C)C(O)C(C)C(=O)C(C)C(O)C(C)C(=O)C(C)(O)C(O)C(C)CC=CC=CC(CC)CCC2OC21CCC(C)C(CC(C)O)O2 MNULEGDCPYONBU-UHFFFAOYSA-N 0.000 description 1
SEHFUALWMUWDKS-UHFFFAOYSA-N 5-fluoroorotic acid Chemical compound OC(=O)C=1NC(=O)NC(=O)C=1F SEHFUALWMUWDKS-UHFFFAOYSA-N 0.000 description 1
101710103970 ADP,ATP carrier protein Proteins 0.000 description 1
101710133192 ADP,ATP carrier protein, mitochondrial Proteins 0.000 description 1
101150037123 APOE gene Proteins 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
108010021809 Alcohol dehydrogenase Proteins 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
102100029470 Apolipoprotein E Human genes 0.000 description 1
101710095339 Apolipoprotein E Proteins 0.000 description 1
102000013918 Apolipoproteins E Human genes 0.000 description 1
108010025628 Apolipoproteins E Proteins 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 description 1
102100026792 Aryl hydrocarbon receptor Human genes 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
108091032955 Bacterial small RNA Proteins 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
101100129088 Caenorhabditis elegans lys-2 gene Proteins 0.000 description 1
101710132601 Capsid protein Proteins 0.000 description 1
208000005623 Carcinogenesis Diseases 0.000 description 1
208000002061 Cardiac Conduction System Disease Diseases 0.000 description 1
208000020446 Cardiac disease Diseases 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
241000701489 Cauliflower mosaic virus Species 0.000 description 1
241000700198 Cavia Species 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
206010011882 Deafness congenital Diseases 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
201000009051 Embryonal Carcinoma Diseases 0.000 description 1
208000032274 Encephalopathy Diseases 0.000 description 1
241000701959 Escherichia virus Lambda Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
101000941893 Felis catus Leucine-rich repeat and calponin homology domain-containing protein 1 Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010064571 Gene mutation Diseases 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
102000005720 Glutathione transferase Human genes 0.000 description 1
108010070675 Glutathione transferase Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101001128158 Homo sapiens Nanos homolog 2 Proteins 0.000 description 1
101001124991 Homo sapiens Nitric oxide synthase, inducible Proteins 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
101150007280 LEU2 gene Proteins 0.000 description 1
235000019687 Lamb Nutrition 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
102000015930 Lon proteases Human genes 0.000 description 1
208000009564 MELAS Syndrome Diseases 0.000 description 1
201000009035 MERRF syndrome Diseases 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
XRYVAQQLDYTHCL-UHFFFAOYSA-N Marini Chemical compound O1C=2C(CC(CC=C(C)C)C(C)=C)=C(O)C=C(O)C=2C(=O)CC1C1=CC=C(O)C=C1O XRYVAQQLDYTHCL-UHFFFAOYSA-N 0.000 description 1
208000036626 Mental retardation Diseases 0.000 description 1
108010006519 Molecular Chaperones Proteins 0.000 description 1
102000005431 Molecular Chaperones Human genes 0.000 description 1
208000001984 Multiple Symmetrical Lipomatosis Diseases 0.000 description 1
108010085220 Multiprotein Complexes Proteins 0.000 description 1
102000007474 Multiprotein Complexes Human genes 0.000 description 1
241001529936 Murinae Species 0.000 description 1
208000029578 Muscle disease Diseases 0.000 description 1
101710107068 Myelin basic protein Proteins 0.000 description 1
206010069825 Myoclonic epilepsy and ragged-red fibres Diseases 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
206010033109 Ototoxicity Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
241000009328 Perro Species 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000007048 Polymyalgia Rheumatica Diseases 0.000 description 1
102000015499 Presenilins Human genes 0.000 description 1
108010050254 Presenilins Proteins 0.000 description 1
241000288906 Primates Species 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
108010023294 Protease La Proteins 0.000 description 1
108010078762 Protein Precursors Proteins 0.000 description 1
102000014961 Protein Precursors Human genes 0.000 description 1
108010001267 Protein Subunits Proteins 0.000 description 1
102000002067 Protein Subunits Human genes 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
208000017442 Retinal disease Diseases 0.000 description 1
206010038923 Retinopathy Diseases 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
108010003581 Ribulose-bisphosphate carboxylase Proteins 0.000 description 1
241000220317 Rosa Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000251131 Sphyrna Species 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
102000003672 Tropomodulin Human genes 0.000 description 1
108090000089 Tropomodulin Proteins 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
YJQCOFNZVFGCAF-UHFFFAOYSA-N Tunicamycin II Natural products O1C(CC(O)C2C(C(O)C(O2)N2C(NC(=O)C=C2)=O)O)C(O)C(O)C(NC(=O)C=CCCCCCCCCC(C)C)C1OC1OC(CO)C(O)C(O)C1NC(C)=O YJQCOFNZVFGCAF-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
UVJPCPROJZIFAV-YAUCMBIBSA-N alpha-L-Rhap-(1->3)-[alpha-L-Rhap-(1->3)-beta-D-Glcp-(1->4)]-alpha-D-Glcp-(1->2)-alpha-D-Glcp Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H]1O UVJPCPROJZIFAV-YAUCMBIBSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
238000003491 array Methods 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
230000001363 autoimmune Effects 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
238000001815 biotherapy Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
238000011685 brown norway rat Methods 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
230000036952 cancer formation Effects 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
210000002932 cholinergic neuron Anatomy 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
238000005094 computer simulation Methods 0.000 description 1
239000005289 controlled pore glass Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
210000003618 cortical neuron Anatomy 0.000 description 1
239000013601 cosmid vector Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000003936 denaturing gel electrophoresis Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000013118 diabetic mouse model Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
238000001085 differential centrifugation Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000029087 digestion Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
210000003027 ear inner Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000009144 enzymatic modification Effects 0.000 description 1
206010015037 epilepsy Diseases 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000004700 fetal blood Anatomy 0.000 description 1
210000003754 fetus Anatomy 0.000 description 1
239000000835 fiber Substances 0.000 description 1
238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000000799 fusogenic effect Effects 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000003633 gene expression assay Methods 0.000 description 1
238000012812 general test Methods 0.000 description 1
102000054766 genetic haplotypes Human genes 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
230000035931 haemagglutination Effects 0.000 description 1
210000003128 head Anatomy 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
210000005260 human cell Anatomy 0.000 description 1
230000003463 hyperproliferative effect Effects 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000000760 immunoelectrophoresis Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000003017 in situ immunoassay Methods 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
208000021267 infertility disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000010354 integration Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
208000006443 lactic acidosis Diseases 0.000 description 1
201000010901 lateral sclerosis Diseases 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
210000002332 leydig cell Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
XIXADJRWDQXREU-UHFFFAOYSA-M lithium acetate Chemical compound [Li+].CC([O-])=O XIXADJRWDQXREU-UHFFFAOYSA-M 0.000 description 1
230000004807 localization Effects 0.000 description 1
101150109301 lys2 gene Proteins 0.000 description 1
230000006674 lysosomal degradation Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000000968 medical method and process Methods 0.000 description 1
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000008437 mitochondrial biogenesis Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000000302 molecular modelling Methods 0.000 description 1
208000005264 motor neuron disease Diseases 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
201000011171 multiple symmetric lipomatosis Diseases 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000006654 negative regulation of apoptotic process Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
230000004766 neurogenesis Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
229930191479 oligomycin Natural products 0.000 description 1
MNULEGDCPYONBU-AWJDAWNUSA-N oligomycin A Polymers O([C@H]1CC[C@H](/C=C/C=C/C[C@@H](C)[C@H](O)[C@@](C)(O)C(=O)[C@@H](C)[C@H](O)[C@@H](C)C(=O)[C@@H](C)[C@H](O)[C@@H](C)/C=C/C(=O)O[C@@H]([C@@H]2C)[C@@H]1C)CC)[C@@]12CC[C@H](C)[C@H](C[C@@H](C)O)O1 MNULEGDCPYONBU-AWJDAWNUSA-N 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
238000010397 one-hybrid screening Methods 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
231100000262 ototoxicity Toxicity 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000004792 oxidative damage Effects 0.000 description 1
230000010627 oxidative phosphorylation Effects 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000009226 pathological process of alzheimers disease Effects 0.000 description 1
230000001991 pathophysiological effect Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
108010079892 phosphoglycerol kinase Proteins 0.000 description 1
230000000243 photosynthetic effect Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
239000013600 plasmid vector Substances 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000001855 preneoplastic effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
238000013197 protein A assay Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
230000003161 proteinsynthetic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000005215 recombination Methods 0.000 description 1
238000006722 reduction reaction Methods 0.000 description 1
230000037425 regulation of transcription Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000002027 skeletal muscle Anatomy 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
210000004927 skin cell Anatomy 0.000 description 1
210000001626 skin fibroblast Anatomy 0.000 description 1
210000003625 skull Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000007787 solid Substances 0.000 description 1
230000000920 spermatogeneic effect Effects 0.000 description 1
210000001323 spiral ganglion Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000010959 steel Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000002381 testicular Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960001322 trypsin Drugs 0.000 description 1
ZHSGGJXRNHWHRS-VIDYELAYSA-N tunicamycin Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](O)[C@@H](CC(O)[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C(NC(=O)C=C2)=O)O)O1)O)NC(=O)/C=C/CC(C)C)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1NC(C)=O ZHSGGJXRNHWHRS-VIDYELAYSA-N 0.000 description 1
MEYZYGMYMLNUHJ-UHFFFAOYSA-N tunicamycin Natural products CC(C)CCCCCCCCCC=CC(=O)NC1C(O)C(O)C(CC(O)C2OC(C(O)C2O)N3C=CC(=O)NC3=O)OC1OC4OC(CO)C(O)C(O)C4NC(=O)C MEYZYGMYMLNUHJ-UHFFFAOYSA-N 0.000 description 1
238000010396 two-hybrid screening Methods 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
239000004474 valine Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000002424 x-ray crystallography Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Diabetes (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Biotechnology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Toxicology (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Cardiology (AREA)
Microbiology (AREA)
Obesity (AREA)
General Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA002332625A 1998-07-10 1999-07-08 Interaction de precurseur de la proteine beta-amyloide humaine (.beta.-app) et de proteine humaine du type lon-protease (hslon) Abandoned CA2332625A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11334898A	1998-07-10	1998-07-10
US09/113,348		1998-07-10
PCT/US1999/015592 WO2000002911A2 (fr)	1998-07-10	1999-07-08	INTERACTION DE PRECURSEUR DE LA PROTEINE BETA-AMYLOIDE HUMAINE (β-APP) ET DE PROTEINE HUMAINE DU TYPE LON-PROTEASE (HsLON)

Publications (1)

Publication Number	Publication Date
CA2332625A1 true CA2332625A1 (fr)	2000-01-20

Family

ID=22348923

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002332625A Abandoned CA2332625A1 (fr)	1998-07-10	1999-07-08	Interaction de precurseur de la proteine beta-amyloide humaine (.beta.-app) et de proteine humaine du type lon-protease (hslon)

Country Status (5)

Country	Link
EP (1)	EP1095154A2 (fr)
JP (1)	JP2002521004A (fr)
AU (1)	AU4869399A (fr)
CA (1)	CA2332625A1 (fr)
WO (1)	WO2000002911A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6379620B1 (en)	1998-11-16	2002-04-30	Barry M. Tydings	Assaying device and method for in field urinalysis
WO2001073057A1 (fr) *	2000-03-24	2001-10-04	Millennium Pharmaceuticals, Inc.	Nouvelle molecule du type atpase appelee 19053 et ses utilisations
CN1315402A (zh) *	2000-03-28	2001-10-03	上海博德基因开发有限公司	一种新的多肽——人淀粉类前体蛋白结合蛋白14和编码这种多肽的多核苷酸
CN1315439A (zh) *	2000-03-29	2001-10-03	上海博德基因开发有限公司	一种新的多肽——人淀粉类前体蛋白结合蛋白9和编码这种多肽的多核苷酸
CN1323833A (zh) *	2000-05-16	2001-11-28	上海博德基因开发有限公司	一种新的多肽——人淀粉类前体蛋白结合蛋白51和编码这种多肽的多核苷酸
ATE554169T1 (de)	2001-11-02	2012-05-15	Giuliani Int Ltd	Smad7-inhibitoren zur behandlung von krankheiten des zns
US6805838B2 (en)	2002-03-04	2004-10-19	Barry M. Tydings	Assaying device and method for in field urinalysis
EP2301959A3 (fr) *	2002-04-09	2013-03-13	The Scripps Research Institute	Polypeptides hybrides à motifs greffés et leurs utilisations
WO2004003150A2 (fr)	2002-06-26	2004-01-08	Yale University	Modulateurs et modulation de l'interaction entre les rgm et la neogenine
DE60333857D1 (de)	2002-10-03	2010-09-30	Neuropharmacology Services Llc	Oxytocin zur Behandlung von Autismus und Asperger-Syndrom
DE602004020855D1 (de)	2003-11-20	2009-06-10	Hoffmann La Roche	Spezifische Marker für Stoffwechselssyndrome
CA2624562A1 (fr)	2005-09-30	2007-04-12	Abbott Gmbh & Co. Kg	Domaines de liaison de proteines de la famille proteinique des molecules de guidage repulsif (rgm), fragments fonctionnels de ces domaines et leur utilisation
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
BR112012013734A2 (pt)	2009-12-08	2017-01-10	Abbott Gmbh & Co Kg	anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
WO2011083147A1 (fr)	2010-01-08	2011-07-14	Cemm-Forschungsinstitut Für Molekulare Medizin Gmbh	Inhibition de wave1 dans l'intervention médicale de maladies inflammatoires et/ou d'infections causées par un pathogène
EP2561068A1 (fr)	2010-04-19	2013-02-27	Medizinische Universität Innsbruck	Tmem195 code pour l'activité alkylglycérol monooxygénase dépendante de la tétrahydrobioptérine
EP2807192B1 (fr)	2012-01-27	2018-04-18	Abbvie Deutschland GmbH & Co. KG	Composition et méthode pour le diagnostic et le traitement de maladies associées à la dégénérescence des neurites
MA54880A (fr) *	2019-02-01	2021-12-08	Avrobio Inc	Compositions et procédés de traitement de troubles neurocognitifs

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3702789A1 (de) *	1987-01-30	1988-08-18	Bayer Ag	Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins

1999
- 1999-07-08 WO PCT/US1999/015592 patent/WO2000002911A2/fr not_active Ceased
- 1999-07-08 AU AU48693/99A patent/AU4869399A/en not_active Abandoned
- 1999-07-08 EP EP99932376A patent/EP1095154A2/fr not_active Withdrawn
- 1999-07-08 CA CA002332625A patent/CA2332625A1/fr not_active Abandoned
- 1999-07-08 JP JP2000559140A patent/JP2002521004A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2002521004A (ja)	2002-07-16
EP1095154A2 (fr)	2001-05-02
WO2000002911A2 (fr)	2000-01-20
WO2000002911A3 (fr)	2001-01-18
AU4869399A (en)	2000-02-01

Publication	Publication Date	Title
CA2332625A1 (fr)	2000-01-20	Interaction de precurseur de la proteine beta-amyloide humaine (.beta.-app) et de proteine humaine du type lon-protease (hslon)
US5977311A (en)	1999-11-02	53BP2 complexes
US20030064477A1 (en)	2003-04-03	Novel E6 targeted protein (E6TP1)
JP2002510490A (ja)	2002-04-09	Ｌｙｓｔタンパク質複合体およびｌｙｓｔ相互作用タンパク質
WO2000050590A1 (fr)	2000-08-31	Proteine capable d'interaction avec un polypeptide mdm et procedes d'utilisation
AU6293799A (en)	2000-04-26	Nlk1 -interacting proteins
CA2309390A1 (fr)	1999-05-27	Proteine cdk2 et complexes a base de proteine cdk2
AU770000B2 (en)	2004-02-12	Hermansky pudlak syndrome protein-interacting proteins and methods of use thereof
AU4690499A (en)	2000-01-05	Interaction of p27(kip1) with fkbp-12
AU760536C (en)	2004-06-17	Chaperone suppression of ataxin-1 aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1
CA2319782A1 (fr)	1999-08-19	Complexes proteiques de retinoblastome et proteines interagissant avec le retinoblastome
JP2005511660A (ja)	2005-04-28	エネルギー恒常性の調節に関与する、ＰＴＰ１０Ｄ、Ｔｅｃタンパク質チロシンキナーゼおよびＥＤＴＰの相同性タンパク質
JP2005511660A6 (ja)	2005-07-21	エネルギー恒常性の調節に関与する、ＰＴＰ１０Ｄ、Ｔｅｃタンパク質チロシンキナーゼおよびＥＤＴＰの相同性タンパク質
CA2309677A1 (fr)	1999-06-03	Nouveaux gene et proteine exprimes dans les tissus nerveux et pancreatiques
JP4709383B2 (ja)	2011-06-22	Ｕｃｐ４
US20050239064A1 (en)	2005-10-27	Methods and compositions based on protein interactions with mastermind
US7342102B2 (en)	2008-03-11	Uncoupling protein 5 (UCP5)
US6967245B2 (en)	2005-11-22	Ucp5
JP2002533062A5 (fr)	2010-04-22
AU3291799A (en)	1999-08-30	Retinoblastoma protein complexes and retinoblastoma interacting proteins

Legal Events

Date	Code	Title	Description
2005-07-08	FZDE	Dead